{"id":"ongoing-cart-regimen","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Nausea"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-30%","effect":"Headache"},{"rate":"10-30%","effect":"Insomnia"},{"rate":"5-20%","effect":"Rash"},{"rate":"5-20%","effect":"Abdominal pain"},{"rate":"5-20%","effect":"Dizziness"},{"rate":"5-20%","effect":"Muscle pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"cART regimens typically consist of a combination of nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), or integrase strand transfer inhibitors (INSTIs). These drugs work by inhibiting viral enzymes necessary for viral replication, thereby reducing the viral load in the body.","oneSentence":"cART regimens combine multiple antiretroviral drugs to suppress HIV replication by targeting different stages of the viral life cycle.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:23.181Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection"}]},"trialDetails":[{"nctId":"NCT03497676","phase":"PHASE1, PHASE2","title":"More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-03","conditions":"HIV Infections","enrollment":168},{"nctId":"NCT04545762","phase":"PHASE1","title":"Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"C. Babis Andreadis","startDate":"2020-09-11","conditions":"Refractory Non-Hodgkin Lymphoma, Burkitt Lymphoma, Mantle Cell Lymphoma","enrollment":36},{"nctId":"NCT02951052","phase":"PHASE3","title":"Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-28","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":618},{"nctId":"NCT05289986","phase":"PHASE4","title":"The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive Patients","status":"TERMINATED","sponsor":"Chelsea and Westminster NHS Foundation Trust","startDate":"2023-11-21","conditions":"Hiv","enrollment":18},{"nctId":"NCT04892654","phase":"PHASE3","title":"Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch","status":"RECRUITING","sponsor":"Chelsea and Westminster NHS Foundation Trust","startDate":"2022-08-17","conditions":"HIV-1-infection","enrollment":150},{"nctId":"NCT03787095","phase":"PHASE1, PHASE2","title":"Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-08-13","conditions":"HIV Infections","enrollment":5},{"nctId":"NCT03160105","phase":"PHASE4","title":"Evaluation of a Simplified Strategy for the Long-term Management of HIV Infection (Simpl'HIV)","status":"COMPLETED","sponsor":"Calmy Alexandra","startDate":"2017-05-19","conditions":"HIV-1-infection, Antiretroviral Therapy, Maintenance Therapy","enrollment":186},{"nctId":"NCT02105987","phase":"PHASE3","title":"A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-04","conditions":"Infection, Human Immunodeficiency Virus","enrollment":555},{"nctId":"NCT01384682","phase":"PHASE4","title":"Maraviroc Switch Collaborative Study","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2011-08","conditions":"HIV","enrollment":399},{"nctId":"NCT02002286","phase":"NA","title":"Safety and Efficacy Study of TwHF in HIV Patients With Poor Immune Responses","status":"COMPLETED","sponsor":"LI Taisheng","startDate":"2011-08","conditions":"HIV","enrollment":23}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ongoing cART regimen","genericName":"Ongoing cART regimen","companyName":"ViiV Healthcare","companyId":"viiv-healthcare","modality":"Small molecule","firstApprovalDate":"","aiSummary":"cART regimens combine multiple antiretroviral drugs to suppress HIV replication by targeting different stages of the viral life cycle. Used for HIV-1 infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}